source
- Australia emerges as a hub for early-stage clinical trials thanks to speed, clear regulations and tax incentivesA recent episode of BioSpace’s Denatured podcast featured Jerome Barley of Avion Medical and Ryan Klein of Resolian discussing Australia’s growing appeal for early-stage clinical development. The…
- BMS drops $80 million neurodegeneration program after phase-1 resultsBMS announced it will not move forward with a neurodegeneration drug it licensed from Prothena, ending a program it invested $80 million in. The drug, known as BMS-986495 (formerly PRX019), comple…